Eicosapentaenoic acid ( DrugBank: Eicosapentaenoic acid )

6 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
96	Crohn disease	1
97	Ulcerative colitis	2
296	Biliary atresia	1
297	Alagille syndrome	1
338	Progressive familial intrahepatic cholestasis	1

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2004-004404-21-GB (EUCTR)	10/12/2004	17/02/2005	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus	Systemic Lupus Erythematosus	Trade Name: Omacor Product Name: Omacor INN or Proposed INN: Eicosapentaenoic acid INN or Proposed INN: Docosahexaenoic acid INN or Proposed INN: alpha-tocopherol	GreenPark Healthcare Trust	Queens University Belfast	Not Recruiting			Female: yes Male: yes	60	Phase 4	United Kingdom

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179372 (ClinicalTrials.gov)	June 2014	29/6/2014	Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases	Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases	Ulcerative Colitis;Crohn's Disease	Dietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	NULL	Completed	18 Years	80 Years	Both	60	N/A	Italy

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179372 (ClinicalTrials.gov)	June 2014	29/6/2014	Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases	Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases	Ulcerative Colitis;Crohn's Disease	Dietary Supplement: Eicosapentaenoic acid;Dietary Supplement: Medium chain fatty acid (placebo)	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	NULL	Completed	18 Years	80 Years	Both	60	N/A	Italy
2	NCT02069561 (ClinicalTrials.gov)	January 2014	19/2/2014	Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer	Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease	Ulcerative Colitis	Dietary Supplement: Eicosapentaenoic Acid	Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi	NULL	Completed	18 Years	70 Years	Both	25	N/A	Italy

Clinical trials : 71 / Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041180088	01/12/2016	12/03/2019	Influence of fatty acid metabolism for clinical course of biliary atresia	The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia	biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.	oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid	Sumida Wataru	Uchida Hiroo	Complete	Not applicable	Not applicable	Both	30	N/A	Japan

Clinical trials : 45 / Drugs : 21 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041180088	01/12/2016	12/03/2019	Influence of fatty acid metabolism for clinical course of biliary atresia	The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia	biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.	oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid	Sumida Wataru	Uchida Hiroo	Complete	Not applicable	Not applicable	Both	30	N/A	Japan

Clinical trials : 60 / Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041180088	01/12/2016	12/03/2019	Influence of fatty acid metabolism for clinical course of biliary atresia	The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia	biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.	oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid	Sumida Wataru	Uchida Hiroo	Complete	Not applicable	Not applicable	Both	30	N/A	Japan